

Active substances set

Search phrase: rituximab

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Chronic lymphoid leukemia

Rituximab

Rituximab in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia (CLL). Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including Rituximab or patients refractory to previous Rituximab plus chemotherapy.



**FULL
REIMBURSEMENT**



ESMO